Currently, only about 20% of all cancer patients will actually benefit from costly immunotherapy. New research can now determine which ones are in that category, simply by analyzing previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy treatment.
from Latest Science News -- ScienceDaily https://ift.tt/3398jOA
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment